Year: 2017
Type: review
Abstract: Over the past 20 years, there has been tremendous progress in retinal gene therapy. The safety and efficacy results in one early-onset severe blinding disease may lead to the first gene therapy drug approval in the United States. Here, we review how far the field has come over the past two decades and speculate on the directions that the field will take in the future.
Source: Molecular Therapy
Author: Jean Bennett
Institution: University of Pennsylvania
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: Choroideremia Research Foundation, F. M. Kirby Foundation, Research to Prevent Blindness, University of Pennsylvania, National Institutes of Health, National Eye Institute, National Institute of Biomedical Imaging and Bioengineering, Center for Advanced Retinal and Ocular Therapeutics, Perelman School of Medicine, University of Pennsylvania
Awards: Longitudinal Neuroimaging of Leber's Congenital Amaurosis After Gene Therapy, Therapeutic approaches for ABCA4-associated disorders, Gene Therapy for Inherited Retinal Degeneration, Broad Spectrum Molecular Therapy for Blinding Retina Disorders, An Inducible System for Gene Delivery, Plasticity of the human visual system studied in response to retinal gene therapy, P30 Core Grant For Vision Research
OpenAlex ID: W2598842955
